STOCK TITAN

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Insider activity: On 07/29/2025, Select Medical Holdings (SEM) Executive Chairman & Director Robert A. Ortenzio received 250,000 restricted shares at $0. The grant vests in three equal annual installments over the next three years.

Post-transaction, Ortenzio owns 7,081,788 shares directly and 2,120,245 shares indirectly through family trusts, for total exposure of roughly 9.2 million shares. No shares were sold and no options or other derivatives were involved.

The award modestly dilutes shareholders (≈0.18% of SEM’s 136 m shares outstanding) but reinforces insider alignment as the founder increases his stake without cash outflow.

Attività degli insider: Il 29/07/2025, Robert A. Ortenzio, Presidente Esecutivo e Direttore di Select Medical Holdings (SEM), ha ricevuto 250.000 azioni vincolate a $0. La concessione si consolida in tre rate annuali uguali nei prossimi tre anni.

Dopo l’operazione, Ortenzio possiede 7.081.788 azioni direttamente e 2.120.245 azioni indirettamente tramite trust familiari, per un’esposizione totale di circa 9,2 milioni di azioni. Non sono state vendute azioni né coinvolte opzioni o altri derivati.

Il premio diluisce modestamente gli azionisti (circa lo 0,18% delle 136 milioni di azioni in circolazione di SEM) ma rafforza l’allineamento degli insider, poiché il fondatore aumenta la sua partecipazione senza esborso di denaro.

Actividad de los insiders: El 29/07/2025, Robert A. Ortenzio, Presidente Ejecutivo y Director de Select Medical Holdings (SEM), recibió 250,000 acciones restringidas a $0. La concesión se consolida en tres cuotas anuales iguales durante los próximos tres años.

Tras la transacción, Ortenzio posee 7,081,788 acciones directamente y 2,120,245 acciones indirectamente a través de fideicomisos familiares, para una exposición total de aproximadamente 9.2 millones de acciones. No se vendieron acciones ni se involucraron opciones u otros derivados.

El premio diluye modestamente a los accionistas (≈0.18% de las 136 millones de acciones en circulación de SEM) pero refuerza la alineación de los insiders, ya que el fundador incrementa su participación sin desembolso de efectivo.

내부자 활동: 2025년 7월 29일, Select Medical Holdings(SEM)의 집행 의장 겸 이사인 Robert A. Ortenzio가 0달러에 250,000 제한 주식을 받았습니다. 이 보상은 향후 3년간 매년 동일한 3회 분할로 권리가 부여됩니다.

거래 후 Ortenzio는 직접 7,081,788주와 가족 신탁을 통한 간접 2,120,245주를 보유해 총 약 920만 주에 해당하는 지분을 보유하게 됩니다. 주식 매각이나 옵션, 기타 파생상품은 포함되지 않았습니다.

이번 보상은 주주 지분을 약간 희석시키지만(SEM의 발행 주식 1억 3,600만 주의 약 0.18%), 창립자가 현금 지출 없이 지분을 늘리면서 내부자 정렬을 강화합니다.

Activité des initiés : Le 29/07/2025, Robert A. Ortenzio, Président exécutif et administrateur de Select Medical Holdings (SEM), a reçu 250 000 actions restreintes à 0 $. La subvention est acquise en trois versements annuels égaux sur les trois prochaines années.

Après la transaction, Ortenzio détient 7 081 788 actions en direct et 2 120 245 actions indirectement via des trusts familiaux, pour une exposition totale d’environ 9,2 millions d’actions. Aucune action n’a été vendue et aucune option ni autre dérivé n’a été impliqué.

Cette attribution dilue modestement les actionnaires (≈0,18 % des 136 millions d’actions en circulation de SEM) mais renforce l’alignement des initiés, le fondateur augmentant sa participation sans sortie de trésorerie.

Insider-Aktivität: Am 29.07.2025 erhielt Robert A. Ortenzio, Executive Chairman & Director von Select Medical Holdings (SEM), 250.000 eingeschränkte Aktien zu einem Preis von 0 $. Die Zuteilung wird in drei gleichen jährlichen Tranchen über die nächsten drei Jahre freigegeben.

Nach der Transaktion besitzt Ortenzio 7.081.788 Aktien direkt und 2.120.245 Aktien indirekt über Familienstiftungen, was einer Gesamtposition von etwa 9,2 Millionen Aktien entspricht. Es wurden keine Aktien verkauft und keine Optionen oder andere Derivate verwendet.

Die Zuteilung verwässert die Aktionäre geringfügig (≈0,18 % von SEMs 136 Mio. ausstehenden Aktien), stärkt jedoch die Interessenangleichung der Insider, da der Gründer seine Beteiligung ohne Geldaufwand erhöht.

Positive
  • Founder/executive increases direct ownership by 250,000 shares through a multi-year restricted-stock grant, aligning incentives with shareholders.
  • Dilution is minor (~0.18% of share count), limiting negative impact on existing holders.
Negative
  • None.

Insights

TL;DR: Restricted-stock grant to founder; positive alignment signal, immaterial dilution.

The Form 4 shows Robert A. Ortenzio adding 250 k restricted shares that vest over three years. Because the grant is at no cost and has a multi-year vesting schedule, it ties the Executive Chairman’s incentives closely to long-term performance. Direct holdings rise to 7.1 m shares—about 5.2% of shares outstanding—while total economic exposure tops 9 m. The incremental dilution (~0.18%) is negligible for investors. Historically, insider purchases or awards that increase ownership, especially by founders, are interpreted as a constructive signal. However, because this is a routine equity-compensation action rather than an open-market buy, market impact should be limited.

Attività degli insider: Il 29/07/2025, Robert A. Ortenzio, Presidente Esecutivo e Direttore di Select Medical Holdings (SEM), ha ricevuto 250.000 azioni vincolate a $0. La concessione si consolida in tre rate annuali uguali nei prossimi tre anni.

Dopo l’operazione, Ortenzio possiede 7.081.788 azioni direttamente e 2.120.245 azioni indirettamente tramite trust familiari, per un’esposizione totale di circa 9,2 milioni di azioni. Non sono state vendute azioni né coinvolte opzioni o altri derivati.

Il premio diluisce modestamente gli azionisti (circa lo 0,18% delle 136 milioni di azioni in circolazione di SEM) ma rafforza l’allineamento degli insider, poiché il fondatore aumenta la sua partecipazione senza esborso di denaro.

Actividad de los insiders: El 29/07/2025, Robert A. Ortenzio, Presidente Ejecutivo y Director de Select Medical Holdings (SEM), recibió 250,000 acciones restringidas a $0. La concesión se consolida en tres cuotas anuales iguales durante los próximos tres años.

Tras la transacción, Ortenzio posee 7,081,788 acciones directamente y 2,120,245 acciones indirectamente a través de fideicomisos familiares, para una exposición total de aproximadamente 9.2 millones de acciones. No se vendieron acciones ni se involucraron opciones u otros derivados.

El premio diluye modestamente a los accionistas (≈0.18% de las 136 millones de acciones en circulación de SEM) pero refuerza la alineación de los insiders, ya que el fundador incrementa su participación sin desembolso de efectivo.

내부자 활동: 2025년 7월 29일, Select Medical Holdings(SEM)의 집행 의장 겸 이사인 Robert A. Ortenzio가 0달러에 250,000 제한 주식을 받았습니다. 이 보상은 향후 3년간 매년 동일한 3회 분할로 권리가 부여됩니다.

거래 후 Ortenzio는 직접 7,081,788주와 가족 신탁을 통한 간접 2,120,245주를 보유해 총 약 920만 주에 해당하는 지분을 보유하게 됩니다. 주식 매각이나 옵션, 기타 파생상품은 포함되지 않았습니다.

이번 보상은 주주 지분을 약간 희석시키지만(SEM의 발행 주식 1억 3,600만 주의 약 0.18%), 창립자가 현금 지출 없이 지분을 늘리면서 내부자 정렬을 강화합니다.

Activité des initiés : Le 29/07/2025, Robert A. Ortenzio, Président exécutif et administrateur de Select Medical Holdings (SEM), a reçu 250 000 actions restreintes à 0 $. La subvention est acquise en trois versements annuels égaux sur les trois prochaines années.

Après la transaction, Ortenzio détient 7 081 788 actions en direct et 2 120 245 actions indirectement via des trusts familiaux, pour une exposition totale d’environ 9,2 millions d’actions. Aucune action n’a été vendue et aucune option ni autre dérivé n’a été impliqué.

Cette attribution dilue modestement les actionnaires (≈0,18 % des 136 millions d’actions en circulation de SEM) mais renforce l’alignement des initiés, le fondateur augmentant sa participation sans sortie de trésorerie.

Insider-Aktivität: Am 29.07.2025 erhielt Robert A. Ortenzio, Executive Chairman & Director von Select Medical Holdings (SEM), 250.000 eingeschränkte Aktien zu einem Preis von 0 $. Die Zuteilung wird in drei gleichen jährlichen Tranchen über die nächsten drei Jahre freigegeben.

Nach der Transaktion besitzt Ortenzio 7.081.788 Aktien direkt und 2.120.245 Aktien indirekt über Familienstiftungen, was einer Gesamtposition von etwa 9,2 Millionen Aktien entspricht. Es wurden keine Aktien verkauft und keine Optionen oder andere Derivate verwendet.

Die Zuteilung verwässert die Aktionäre geringfügig (≈0,18 % von SEMs 136 Mio. ausstehenden Aktien), stärkt jedoch die Interessenangleichung der Insider, da der Gründer seine Beteiligung ohne Geldaufwand erhöht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Lai

(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR

(Street)
BASEL V8 4051

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Global Head of R&D
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 1,023,529 D
Ordinary Shares 666,965 I See Footnote(1)
RMB Shares(2) 0(3)(4) I See Footnote(4)
American Depositary Shares(5) 07/29/2025 S(6) 2,949 D $301.9993(7) 1,351 I See Footnote(1)
American Depositary Shares(5) 07/29/2025 S(6) 292 D $302.9249(8) 1,059 I See Footnote(1)
American Depositary Shares(5) 07/29/2025 S(6) 800 D $304.163(9) 259 I See Footnote(1)
American Depositary Shares(5) 07/30/2025 S(6) 259 D $305 0 I See Footnote(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
2. The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
3. The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
4. The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
5. Each American Depositary Share represents 13 Ordinary Shares.
6. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.74 to $302.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.76 to $303.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.94 to $304.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did SEM’s Executive Chairman acquire?

Robert A. Ortenzio received 250,000 restricted shares on 07/29/2025.

What is Ortenzio’s total ownership in SEM after the grant?

He now holds 7,081,788 shares directly plus 2,120,245 indirectly, totaling ≈9.2 million shares.

Does the grant involve cash outlay or option exercise?

No; the shares were granted at $0 under the company’s equity plan.

When will the restricted shares vest?

They vest in three equal annual installments over the next three years.

What is the potential dilution from this issuance?

Approximately 0.18% of SEM’s ~136 million shares outstanding.
Beigene Ltd

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data

32.46B
90.63M
19.24%
42.54%
2.36%
Biotechnology
Pharmaceutical Preparations
Link
Cayman Islands
GRAND CAYMAN